# A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

> **NCT04161898** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 56 (estimated)

## Conditions studied

- Takayasu Arteritis (TAK)

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Placebo for Upadacitinib
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT04161898
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-04
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04161898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04161898, "A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04161898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*